Kernal Biologics co-founders Yusuf Erkul (L) and Burak Yilmaz

Push­ing mR­NA ther­a­peu­tics for can­cer, Cam­bridge start­up nabs Se­ries A to ex­plore next-gen ap­proach

With in­creased in­ter­est in mR­NA ther­a­peu­tics thanks to Pfiz­er and Mod­er­na’s megablock­buster Covid-19 vac­cines, a new start­up lo­cat­ed next to MIT is get­ting in­fused with cash as it looks to go in­to the clin­ic.

Ker­nal Bio put out word Thurs­day morn­ing that it had com­plet­ed a $25 mil­lion Se­ries A round, led by Hum­ming­bird Ven­tures. The new cap­i­tal, which should last Ker­nal about two and a half years, will ex­tend Ker­nal’s “mR­NA 2.0” plat­form and sup­port an IND fil­ing for Ker­nal’s I/O can­di­date KR-335.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.